These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21349712)

  • 21. Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile.
    Rosen J; Negro-Vilar A
    J Musculoskelet Neuronal Interact; 2002 Mar; 2(3):222-4. PubMed ID: 15758439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and structure-activity relationships of a series of 2-Ar-8-methyl-5-alkylaminoquinolines as novel CRF₁ receptor antagonists.
    Takeda K; Terauchi T; Hashizume M; Shin K; Ino M; Shibata H; Yonaga M
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5372-8. PubMed ID: 22871582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the development of selective androgen receptor modulators.
    Zhang X; Lanter JC; Sui Z
    Expert Opin Ther Pat; 2009 Sep; 19(9):1239-58. PubMed ID: 19505196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
    Dai J; Shen R; Sumitomo M; Stahl R; Navarro D; Gershengorn MC; Nanus DM
    Clin Cancer Res; 2002 Jul; 8(7):2399-405. PubMed ID: 12114445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators.
    Kim J; Wu D; Hwang DJ; Miller DD; Dalton JT
    J Pharmacol Exp Ther; 2005 Oct; 315(1):230-9. PubMed ID: 15987833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.
    Schlienger N; Lund BW; Pawlas J; Badalassi F; Bertozzi F; Lewinsky R; Fejzic A; Thygesen MB; Tabatabaei A; Bradley SR; Gardell LR; Piu F; Olsson R
    J Med Chem; 2009 Nov; 52(22):7186-91. PubMed ID: 19856921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.
    Chen J; Ding K; Levant B; Wang S
    Bioorg Med Chem Lett; 2006 Jan; 16(2):443-6. PubMed ID: 16290142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, and preliminary pharmacological evaluation of new quinoline derivatives as nicotinic ligands.
    Guandalini L; Norcini M; Varani K; Pistolozzi M; Gotti C; Bazzicalupi C; Martini E; Dei S; Manetti D; Scapecchi S; Teodori E; Bertucci C; Ghelardini C; Romanelli MN
    J Med Chem; 2007 Oct; 50(20):4993-5002. PubMed ID: 17850058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.
    Yang Y; Shi L; Zhou Y; Li HQ; Zhu ZW; Zhu HL
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6653-6. PubMed ID: 20943391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacodynamics of selective androgen receptor modulators.
    Yin D; Gao W; Kearbey JD; Xu H; Chung K; He Y; Marhefka CA; Veverka KA; Miller DD; Dalton JT
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1334-40. PubMed ID: 12604714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetrahydroquinoline glucocorticoid receptor agonists: discovery of a 3-hydroxyl for improving receptor selectivity.
    Roach SL; Higuchi RI; Hudson AR; Adams ME; Syka PM; Mais DE; Miner JN; Marschke KB; Zhi L
    Bioorg Med Chem Lett; 2011 Jan; 21(1):168-71. PubMed ID: 21115247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C19-steroids as androgen receptor modulators: design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists.
    Marwah P; Marwah A; Lardy HA; Miyamoto H; Chang C
    Bioorg Med Chem; 2006 Sep; 14(17):5933-47. PubMed ID: 16759873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.
    Martinborough E; Shen Y; Oeveren Av; Long YO; Lau TL; Marschke KB; Chang WY; López FJ; Vajda EG; Rix PJ; Viveros OH; Negro-Vilar A; Zhi L
    J Med Chem; 2007 Oct; 50(21):5049-52. PubMed ID: 17887661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and characterization of nonsteroidal glucocorticoid receptor modulators for multiple myeloma.
    Hudson AR; Roach SL; Higuchi RI; Phillips DP; Bissonnette RP; Lamph WW; Yen J; Li Y; Adams ME; Valdez LJ; Vassar A; Cuervo C; Kallel EA; Gharbaoui CJ; Mais DE; Miner JN; Marschke KB; Rungta D; Negro-Vilar A; Zhi L
    J Med Chem; 2007 Sep; 50(19):4699-709. PubMed ID: 17705362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines.
    Kym PR; Kort ME; Coghlan MJ; Moore JL; Tang R; Ratajczyk JD; Larson DP; Elmore SW; Pratt JK; Stashko MA; Falls HD; Lin CW; Nakane M; Miller L; Tyree CM; Miner JN; Jacobson PB; Wilcox DM; Nguyen P; Lane BC
    J Med Chem; 2003 Mar; 46(6):1016-30. PubMed ID: 12620078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a new class of selective nonsteroidal progesterone receptor agonists.
    Dong Y; Roberge JY; Wang Z; Wang X; Tamasi J; Dell V; Golla R; Corte JR; Liu Y; Fang T; Anthony MN; Schnur DM; Agler ML; Dickson JK; Lawrence RM; Prack MM; Seethala R; Feyen JH
    Steroids; 2004 Mar; 69(3):201-17. PubMed ID: 15072922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective androgen receptor modulators in preclinical and clinical development.
    Narayanan R; Mohler ML; Bohl CE; Miller DD; Dalton JT
    Nucl Recept Signal; 2008; 6():e010. PubMed ID: 19079612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anabolic-androgenic steroid interaction with rat androgen receptor in vivo and in vitro: a comparative study.
    Feldkoren BI; Andersson S
    J Steroid Biochem Mol Biol; 2005 Apr; 94(5):481-7. PubMed ID: 15876413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.